Novocure Announced Positive Topline Results from Phase 3 PANOVA-3 Trial

Novocure Reports Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

The PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated with TTFields in combination with gemcitabine and nab-paclitaxel as a first-line therapy.

Novocure intends to seek regulatory approval for this treatment in the U.S., EU, Japan, and other key markets.

Complete results from the PANOVA-3 trial will be presented at an upcoming medical congress.

Novocure (NASDAQ: NVCR) announced that the Phase 3 PANOVA-3 trial met its primary endpoint, showing a significant improvement in median overall survival (mOS) compared to the control group. The trial evaluated the combination of Tumor Treating Fields (TTFields) therapy with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

“As a researcher and clinician, I have experienced the challenges of developing treatments in pancreatic cancer. It is exciting to see the PANOVA-3 trial achieve the positive primary endpoint of overall survival, a landmark outcome for this field. These data for Tumor Treating Fields are very promising, especially in this difficult to treat patient population.” – said Vincent Picozzi, medical oncologist and investigator in the PANOVA-3 trial.

About PANOVA-3

PANOVA-3 is a prospective, randomized, open-label, controlled Phase 3 clinical trial aimed at evaluating the effectiveness and safety of Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel as a first-line treatment for locally advanced pancreatic adenocarcinoma. Participants were randomly assigned to receive either TTFields therapy alongside gemcitabine and nab-paclitaxel, or gemcitabine and nab-paclitaxel alone.

The primary endpoint is overall survival, while secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity.

A total of 571 patients were enrolled in the trial, with a 1:1 randomization, and were followed for at least 18 months.

About PANOVA-4

PANOVA-4 is an international, multi-center Phase 2 clinical trial designed to assess the safety and efficacy of Tumor Treating Fields (TTFields) therapy in combination with atezolizumab, gemcitabine, and nab-paclitaxel for treating metastatic pancreatic cancer. The primary endpoint is the disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study aims to enroll 76 patients.

About Novocure

Novocure is a global oncology company focused on improving survival rates for some of the most aggressive cancers by developing and commercializing its innovative therapy, Tumor Treating Fields. The company’s approved products are available in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma. Novocure is also conducting several ongoing or completed clinical trials to investigate the use of Tumor Treating Fields therapy in treating glioblastoma, non-small cell lung cancer, and pancreatic cancer.

Further Reading:

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Pancreatic Cancer: What patients should know about

Immunotherapy for Pancreatic Cancer